Neurocrine To Refile Electronic NDA For Indiplon After Meeting With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA refuses to file application for the immediate-release formulation of Pfizer/Neurocrine's insomnia agent "due to difficulties encountered in navigating the electronic NDA," Neurocrine says. An NDA for the modified-release formulation is under review and will require "modest" changes, company says.
You may also be interested in...
FDA Extends Agilect User Fee Deadline Due To “Technical Error”
FDA is extending the user fee deadline for Teva's Parkinson's disease agent Agilect (rasagiline) by three months following the firm's submission of additional data to clarify a "technical error.
FDA Extends Agilect User Fee Deadline Due To “Technical Error”
FDA is extending the user fee deadline for Teva's Parkinson's disease agent Agilect (rasagiline) by three months following the firm's submission of additional data to clarify a "technical error.
Takeda Sales Force Size For Ramelteon Will Depend On Competitor Detailing
To develop a launch strategy for the insomnia agent, Takeda says it will consider the promotional efforts for Sepracor's Lunesta and for indiplon, which Pfizer and Neurocrine expect to refile with FDA in March/April. Takeda predicts a fall launch for ramelteon.